ClinicalTrials.gg
CompletedNCT00680992Updated Sep 22, 2022Results posted

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

A Phase 2 interventional study of Denosumab in Cancer, Giant Cell Tumors and Giant Cell Tumor of Bone, sponsored by Amgen. Completed at 33 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-09-22.

Primary conditionGiant Cell Tumor of BoneRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Giant Cell Tumor of Bone
Why
  1. The study's listed conditions name Giant Cell Tumor of Bone, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
535
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

To determine how safe denosumab is in treating subjects with giant cell tumor of bone (GCTB)

Read the detailed description

To determine how safe denosumab is in treating subjects with GCTB

02

Conditions studied

  • Cancer
  • Giant Cell Tumors
  • Giant Cell Tumor of Bone
  • Benign Giant Cell Tumors

Browse trials for

Keywords

  • Giant Cell Tumor of Bone
03

In context

Giant Cell Tumor of Bone Reclassified

23 studies on the registry are indexed under Giant Cell Tumor of Bone; 7 are open to participants now.

This study's enrollment of 535 is above the median of 43 across 16 interventional studies indexed under Giant Cell Tumor of Bone.

Browse Giant Cell Tumor of Bone studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Giant Cell Tumor of Bone, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed GCTB within 1 year before study enrollment
  • Measurable evidence of active disease within 1 year before study enrollment
  • Subjects with surgically unsalvageable disease (eg, sacral, spinal GCTB, or multiple lesions including pulmonary ) OR subjects whose planned surgery includes joint resection, limb amputation, hemipelvectomy or surgical procedure resulting in severe morbidity
  • performance status equal or greater than 50% (ie, status 0, 1, or 2)
  • Adults or skeletally mature adolescents (ie, radiographic evidence of at least 1 mature long bone [eg, humerus with closed growth epiphyseal plate]) equal or greater than 12 years of age
  • Skeletally mature adolescents must weigh at least 45 kg
  • Before any study-specific procedure is performed, the appropriate written must be obtained

Exclusion criteria

Exclusion criteria:

  • Currently receiving other GCTB specific treatment (eg, radiation, chemotherapy, or embolization)
  • Concurrent bisphosphonate treatment
  • Known or suspected current diagnosis of underlying including high grade sarcoma, osteosarcoma, fibrosarcoma, malignant giant cell sarcoma
  • Known or suspected current diagnosis of non GCTB giant cell-rich tumors
  • Known or suspected current diagnosis of brown cell tumor of bone or Paget's disease
  • Known diagnosis of second malignancy within the past 5 years (subjects with definitively treated basal cell carcinoma and cervical carcinoma in situ are permitted)
  • Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw
  • Active dental or jaw condition which requires oral surgery, including tooth extraction
  • Non-healed dental/oral surgery
  • Planned invasive dental procedure for the course of the study
  • Subject currently is enrolled in or has not yet completed at least 30 days since ending other device or drug study(s), or subject is receiving other investigational agent(s)
  • Subject has known sensitivity to any of the products to be administered during dosing
  • Unstable systemic disease including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months before enrollment
  • Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
  • Female subject of child bearing potential is not willing to use two methods of highly effective during treatment and for 5 months after the end of treatment
  • Subject has any kind of disorder that compromises the ability of the subject to give written and/or to comply with study procedures
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
535 participants (actual)

Study arms

  • Experimental
    Denosumab

    120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.

    Drug: Denosumab

Interventions

  • 120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.

    Also known as: AMG 162, Immunoglobulin G2 human monoclonal antibody to RANK ligand

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    AE defined as any untoward medical occurrence in a clinical trial participant. Serious AE defined as AE that is fatal, life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or other significant medical hazard. Severity of AEs assessed according to Common Terminology Criteria for Adverse Events (CTCAE, v3.0) based on the general guideline: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening or disabling; Grade 5: Death related to AE. Investigator assessed AEs for relatedness to study drug. Results are presented for treatment-emergent events (TEAEs) and included all AEs occurring from first dose in initial treatment phase to end of initial treatment phase (or for participants entering retreatment, from first dose in initial treatment phase until end of retreatment phase).

    Time frame: From first dose of study drug up to last study visit for treatment-emergent period (a maximum of approximately 111 months).

  2. Number of Participants Who Experienced the Maximum Toxicity Grade (CTCAE Grade ≥ 3) in the Indicated Clinical Chemistry Parameters

    Serum samples for clinical chemistry were collected on study day 1 (baseline), day 15, week 5 and each study visit Q4W thereafter until last study visit for the on-study period (ie, until end of initial treatment phase). The parameters included albumin, calcium (albumin-adjusted), creatinine, magnesium and phosphate. Results are presented for number of participants who experienced the maximum toxicity grade for each of these clinical parameters. The maximum toxicity grade experienced by each participant was based on CTCAE, v3.0, and are summarized for Grade 3 and 4. Increases and decreases in relationship to the normal parameter ranges are indicated as 'Above' and 'Below' respectively.

    Time frame: Baseline (day 1) up to last study visit for initial treatment phase (median duration approximately 30 months up to a maximum of approximately 109 months).

Secondary outcomes

  1. Time to Disease Progression or Recurrence During the On-Study Period for Cohort 1, Presented as Kaplan-Meier Estimates of Probability

    Time to disease progression or recurrence during the on-study period was defined as the time interval (in days) from the date of first dose of study drug to the date of earliest Progressive Disease (PD) during the initial treatment phase. PD was defined as the response of progressive disease, locally recurrent disease or relapse as captured in the Disease Status page of the Case Report Form. If a participant had not had PD by the end of the initial treatment phase date, time to disease progression or recurrence were censored at her/his end of initial treatment phase date. Since median time to disease progression or recurrence for participants in cohort 1 was not reached, Kaplan-Meier estimates for the probability (expressed as a percentage) of participants in cohort 1 to have disease progression or recurrence at months 6, 12, 24, 36 and 60 are presented.

    Time frame: From first dose of study drug up to the end of the initial treatment phase (median duration approximately 30 months up to a maximum of approximately 109 months).

  2. Percentage of Participants Without Any On-Study Surgery at Month 6 for Cohort 2

    The percentage of participants without any surgery at month 6 was equivalent to the number of participants without any surgery by month 6 divided by the number of cohort 2 participants who had an opportunity to complete 6 months of treatment, expressed as a percentage.

    Time frame: At month 6.

  3. Mean Serum Denosumab Trough Concentrations

    Blood samples for determination of serum denosumab concentration levels were obtained from participants included in the pharmacokinetic (PK) substudy at baseline (prior to administration of study drug on day 1) and at scheduled time points during the study up to week 25.

    Time frame: Blood samples were collected at baseline (day 1), days 8 and 15 and weeks 5, 9, 13 and 25.

07

Results

Posted Dec 10, 2018

Participant flow

Adults and skeletally mature adolescents (≥12 years of age) were enrolled in this open-label single-arm study. The study was conducted at 30 centers in North America, Europe, and Australia from 09 Sep 2008 to study completion on 17 May 2018. The planned study duration for each participant was at least 60 months (following protocol amendment 7).

Participant flow — Overall Study
MilestoneCohort 1 (Denosumab 120 mg Q4W)Cohort 2 (Denosumab 120 mg Q4W)Cohort 3 (Denosumab 120 mg Q4W)
Started26825212
Safety analysis set26524912
Efficacy analysis set26024211
Completed000
Not completed26825212
Withdrew: Complete resection (as per protocol)251210
Withdrew: Administrative decision83425
Withdrew: End of trial32123
Withdrew: Withdrawal by subject33111
Withdrew: Adverse event21191
Withdrew: Other19141
Withdrew: Disease progression2190
Withdrew: Lost to follow-up12140
Withdrew: Noncompliance460
Withdrew: Requirement for alternative therapy820
Withdrew: Pregnancy501
Withdrew: Death510
Withdrew: Ineligibility determined010

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

AE defined as any untoward medical occurrence in a clinical trial participant. Serious AE defined as AE that is fatal, life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or other significant medical hazard. Severity of AEs assessed according to Common Terminology Criteria for Adverse Events (CTCAE, v3.0) based on the general guideline: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening or disabling; Grade 5: Death related to AE. Investigator assessed AEs for relatedness to study drug. Results are presented for treatment-emergent events (TEAEs) and included all AEs occurring from first dose in initial treatment phase to end of initial treatment phase (or for participants entering retreatment, from first dose in initial treatment phase until end of retreatment phase).

Time frame:
From first dose of study drug up to last study visit for treatment-emergent period (a maximum of approximately 111 months).
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsCohort 1 (Denosumab 120 mg Q4W)Cohort 2 (Denosumab 120 mg Q4W)Cohort 3 (Denosumab 120 mg Q4W)
Any TEAE26023112
Serious TEAE98395
Fatal TEAE830
TEAE leading to treatment phase discontinuation27241
TEAE leading to study drug discontinuation27231
CTCAE Grade 3, 4, or 5121596
Any TEAE related to study drug1841369
PrimaryNumber of Participants Who Experienced the Maximum Toxicity Grade (CTCAE Grade ≥ 3) in the Indicated Clinical Chemistry Parameters

Serum samples for clinical chemistry were collected on study day 1 (baseline), day 15, week 5 and each study visit Q4W thereafter until last study visit for the on-study period (ie, until end of initial treatment phase). The parameters included albumin, calcium (albumin-adjusted), creatinine, magnesium and phosphate. Results are presented for number of participants who experienced the maximum toxicity grade for each of these clinical parameters. The maximum toxicity grade experienced by each participant was based on CTCAE, v3.0, and are summarized for Grade 3 and 4. Increases and decreases in relationship to the normal parameter ranges are indicated as 'Above' and 'Below' respectively.

Time frame:
Baseline (day 1) up to last study visit for initial treatment phase (median duration approximately 30 months up to a maximum of approximately 109 months).
Reported as:
Number · Participants
Number of Participants Who Experienced the Maximum Toxicity Grade (CTCAE Grade ≥ 3) in the Indicated Clinical Chemistry Parameters
ParticipantsCohort 1 (Denosumab 120 mg Q4W)Cohort 2 (Denosumab 120 mg Q4W)Cohort 3 (Denosumab 120 mg Q4W)
Calcium corrected Grade 3 (Above)010
Calcium corrected Grade 4 (Above)110
Calcium corrected Grade 3 (Below)100
Calcium corrected Grade 4 (Below)200
Phosphate Grade 3 (Below)60414
Magnesium Grade 3 (Above)452
Magnesium Grade 3 (Below)100
Creatinine Grade 3 (Above)010
Albumin Grade 3 (Below)100
SecondaryTime to Disease Progression or Recurrence During the On-Study Period for Cohort 1, Presented as Kaplan-Meier Estimates of Probability

Time to disease progression or recurrence during the on-study period was defined as the time interval (in days) from the date of first dose of study drug to the date of earliest Progressive Disease (PD) during the initial treatment phase. PD was defined as the response of progressive disease, locally recurrent disease or relapse as captured in the Disease Status page of the Case Report Form. If a participant had not had PD by the end of the initial treatment phase date, time to disease progression or recurrence were censored at her/his end of initial treatment phase date. Since median time to disease progression or recurrence for participants in cohort 1 was not reached, Kaplan-Meier estimates for the probability (expressed as a percentage) of participants in cohort 1 to have disease progression or recurrence at months 6, 12, 24, 36 and 60 are presented.

Time frame:
From first dose of study drug up to the end of the initial treatment phase (median duration approximately 30 months up to a maximum of approximately 109 months).
Reported as:
Number · Percent probability
Time to Disease Progression or Recurrence During the On-Study Period for Cohort 1, Presented as Kaplan-Meier Estimates of Probability
Percent probabilityCohort 1 (Denosumab 120 mg Q4W)
Month 61.9 (0.3 to 3.6)
Month 124.3 (1.8 to 6.8)
Month 246.1 (3.1 to 9.0)
Month 368.2 (4.6 to 11.8)
Month 6011.7 (7.1 to 16.2)
SecondaryPercentage of Participants Without Any On-Study Surgery at Month 6 for Cohort 2

The percentage of participants without any surgery at month 6 was equivalent to the number of participants without any surgery by month 6 divided by the number of cohort 2 participants who had an opportunity to complete 6 months of treatment, expressed as a percentage.

Time frame:
At month 6.
Reported as:
Number · Percentage of participants
Percentage of Participants Without Any On-Study Surgery at Month 6 for Cohort 2
Percentage of participantsCohort 2 (Denosumab 120 mg Q4W)
Percentage of Participants Without Any On-Study Surgery at Month 6 for Cohort 292.0 (87.8 to 95.1)
SecondaryMean Serum Denosumab Trough Concentrations

Blood samples for determination of serum denosumab concentration levels were obtained from participants included in the pharmacokinetic (PK) substudy at baseline (prior to administration of study drug on day 1) and at scheduled time points during the study up to week 25.

Time frame:
Blood samples were collected at baseline (day 1), days 8 and 15 and weeks 5, 9, 13 and 25.
Reported as:
Mean · nanograms / milliliter
Mean Serum Denosumab Trough Concentrations
nanograms / milliliterAdolescent PK Subset (Denosumab 120 mg Q4W)Adult PK Subset (Denosumab 120 mg Q4W)
Day 10.0 ± 0.00.0 ± 0.0
Day 811800 ± 413012000 ± 4300
Day 1521800 ± 562024200 ± 9050
Week 530400 ± 615033500 ± 8970
Week 925100 ± 645030000 ± 10300
Week 1322300 ± 684029100 ± 10000
Week 1723600 ± 437028300 ± 11600
Week 2522400 ± 669025400 ± 10800

Adverse events

Collected over From first dose of study drug until last study visit; a maximum of approximately 113 months. The planned study duration for each participant was at least 60 months (following protocol amendment 7).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab 120 mg Q4W (All Cohorts)26/526 (4.9%)176/526 (33.5%)480/526 (91.3%)
Most frequent serious events
Showing 10 of 196
Most frequent serious events
EventDenosumab 120 mg Q4W (All Cohorts)
Osteonecrosis of jawMusculoskeletal and connective tissue disorders25/526
Bone giant cell tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)19/526
AnaemiaBlood and lymphatic system disorders8/526
ArthralgiaMusculoskeletal and connective tissue disorders5/526
Back painMusculoskeletal and connective tissue disorders5/526
SarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/526
DeathGeneral disorders4/526
PyrexiaGeneral disorders4/526
AppendicitisInfections and infestations4/526
Device related infectionInfections and infestations4/526
Most frequent other events
Showing 10 of 43
Most frequent other events
EventDenosumab 120 mg Q4W (All Cohorts)
ArthralgiaMusculoskeletal and connective tissue disorders192/526
Back painMusculoskeletal and connective tissue disorders154/526
Pain in extremityMusculoskeletal and connective tissue disorders146/526
FatigueGeneral disorders142/526
HeadacheNervous system disorders134/526
NauseaGastrointestinal disorders122/526
NasopharyngitisInfections and infestations76/526
Musculoskeletal painMusculoskeletal and connective tissue disorders70/526
ToothacheGastrointestinal disorders68/526
VomitingGastrointestinal disorders66/526

Baseline characteristics

The overall baseline population consisted of the 532 participants enrolled into the treatment phase of the study.

Age, Categorical
Age, Categorical(Participants)Cohort 1 (Denosumab 120 mg Q4W)Cohort 2 (Denosumab 120 mg Q4W)Cohort 3 (Denosumab 120 mg Q4W)Total
<=18 years1414028
Between 18 and 65 years23823112481
>=65 years167023
Age, Continuous
Age, Continuous(Years)Cohort 1 (Denosumab 120 mg Q4W)Cohort 2 (Denosumab 120 mg Q4W)Cohort 3 (Denosumab 120 mg Q4W)Total
Mean36.4 ± 14.635.1 ± 13.536.1 ± 14.935.8 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (Denosumab 120 mg Q4W)Cohort 2 (Denosumab 120 mg Q4W)Cohort 3 (Denosumab 120 mg Q4W)Total
Female1541425301
Male1141107231
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 (Denosumab 120 mg Q4W)Cohort 2 (Denosumab 120 mg Q4W)Cohort 3 (Denosumab 120 mg Q4W)Total
White or Caucasian22120811440
Black or African American1812030
Hispanic or Latino1313127
Asian1114025
Native Hawaiian or Other Pacific Islander0101
Other5409
GCTB Disease Type
GCTB Disease Type(Participants)Cohort 1 (Denosumab 120 mg Q4W)Cohort 2 (Denosumab 120 mg Q4W)Cohort 3 (Denosumab 120 mg Q4W)Total
Primary resectable01670167
Primary unresectable930295
Recurrent resectable085085
Recurrent unresectable175010185
08

Study locations

33 sites
  • Research Site
    Santa Monica, California 90403, United States
  • Research Site
    Stanford, California 94305, United States
  • Research Site
    Washington, District of Columbia 20010, United States
  • Research Site
    Gainesville, Florida 32607, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Minneapolis, Minnesota 55455, United States
  • Research Site
    New York, New York 10003, United States
  • Research Site
    Philadelphia, Pennsylvania 19106, United States
  • Research Site
    Greenville, South Carolina 29605, United States
  • Research Site
    Camperdown, New South Wales 2250, Australia
  • Research Site
    Woolloongabba, Queensland 4102, Australia
  • Research Site
    East Melbourne, Victoria 3002, Australia
  • Research Site
    Nedlands, Western Australia 6009, Australia
  • Research Site
    Wien, 1090, Austria
  • Research Site
    Toronto, Ontario M5G 1X5, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Lyon cedex 8, 69373, France
  • Research Site
    Marseille cedex 05, 13385, France
  • Research Site
    Villejuif cedex, 94805, France
  • Research Site
    Bad Saarow, 15526, Germany
  • Research Site
    Stuttgart, 70174, Germany
  • Research Site
    Bologna, 40136, Italy
  • Research Site
    Milano, 20133, Italy
  • Research Site
    Leiden, 2333 ZA, Netherlands
  • Research Site
    Warszawa, 01-211, Poland
  • Research Site
    Warszawa, 02-781, Poland
  • Research Site
    Palma de Mallorca, Baleares 07010, Spain
  • Research Site
    Barcelona, Cataluña 08025, Spain
  • Research Site
    Valencia, Comunidad Valenciana 46026, Spain
  • Research Site
    Lund, 221 85, Sweden
  • Research Site
    Birmingham, B31 2AP, United Kingdom
09

References and documents

Publications

  • Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013 Aug;14(9):901-8. doi: 10.1016/S1470-2045(13)70277-8. Epub 2013 Jul 16. PubMed 23867211 ↗
  • Martin-Broto J, Cleeland CS, Glare PA, Engellau J, Skubitz KM, Blum RH, Ganjoo KN, Staddon A, Dominkus M, Feng A, Qian Y, Braun A, Jacobs I, Chung K, Atchison C. Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study. Acta Oncol. 2014 Sep;53(9):1173-9. doi: 10.3109/0284186X.2014.910313. Epub 2014 May 19. PubMed 24834795 ↗
  • Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, Roberts ZJ, Bach BA. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol. 2015 Sep;22(9):2860-8. doi: 10.1245/s10434-015-4634-9. Epub 2015 Jun 2. PubMed 26033180 ↗
  • Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. doi: 10.1016/S1470-2045(19)30663-1. Epub 2019 Nov 6. PubMed 31704134 ↗
  • Engellau J, Seeger L, Grimer R, Henshaw R, Gelderblom H, Choy E, Chawla S, Reichardt P, O'Neal M, Feng A, Jacobs I, Roberts ZJ, Braun A, Bach BA. Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone. World J Surg Oncol. 2018 Sep 19;16(1):191. doi: 10.1186/s12957-018-1478-3. PubMed 30231890 ↗
  • Bukata SV, Blay JY, Rutkowski P, Skubitz K, Henshaw R, Seeger L, Dai T, Jandial D, Chawla S. Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum. Spine (Phila Pa 1976). 2021 Mar 1;46(5):277-284. doi: 10.1097/BRS.0000000000003728. PubMed 33038190 ↗
  • Palmerini E, Seeger LL, Gambarotti M, Righi A, Reichardt P, Bukata S, Blay JY, Dai T, Jandial D, Picci P. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab. BMC Cancer. 2021 Jan 22;21(1):89. doi: 10.1186/s12885-020-07739-8. PubMed 33482769 ↗
  • Uday S, Gaston CL, Rogers L, Parry M, Joffe J, Pearson J, Sutton D, Grimer R, Hogler W. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone. J Clin Endocrinol Metab. 2018 Feb 1;103(2):596-603. doi: 10.1210/jc.2017-02025. PubMed 29211870 ↗
  • van der Heijden L, van de Sande MA, Hogendoorn PC, Gelderblom H, Dijkstra PD. Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report. Acta Orthop. 2015 Jun;86(3):393-5. doi: 10.3109/17453674.2014.1002345. Epub 2015 Feb 14. No abstract available. PubMed 25684041 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2008 to primary completion in May 2018, 116 months.

Results were first posted in Dec 2018, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2008
First posted
May 20, 2008
StartActual
Sep 9, 2008
Primary completionActual
May 17, 2018
CompletionActual
May 17, 2018
Results first posted
Dec 10, 2018
Last update
Sep 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00680992
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 20, 2008
Start date
Sep 9, 2008
Primary completion
May 17, 2018
Completion
May 17, 2018
Results posted
Dec 10, 2018
Last update
Sep 22, 2022

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion